VF
SPRO icon

Virtu Financial’s Spero Therapeutics SPRO Stock Holding History

Virtu Financial’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-46,046
Closed -$47K – 1993
2024
Q4 		$47K Buy
+46,046
New +$54.8K ﹤0.01% 1173
2024
Q2 		– Sell
-18,180
Closed -$31K – 1848
2024
Q1 		$31K Buy
+18,180
New +$28.5K ﹤0.01% 1101
2023
Q3 		– Sell
-22,195
Closed -$32K – 1861
2023
Q2 		$32K Buy
+22,195
New +$38K ﹤0.01% 1192
2023
Q1 		– Sell
-34,369
Closed -$59K – 2069
2022
Q4 		$59K Buy
+34,369
New +$64.2K 0.01% 1051
2019
Q2 		– Sell
-10,465
Closed -$134K – 1835
2019
Q1 		$134K Buy
+10,465
New +$111K 0.01% 1084

Other funds holding SPRO

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Virtu Financial's SPRO Position: Q1 2025 in Review

Virtu Financial sold out of Spero Therapeutics (SPRO) in Q1 2025, closing a stake of 46,046 shares — an estimated $47K sold.

Virtu Financial first reported a position in SPRO in Q1 2019 and held it in 5 quarters. The position peaked at $134K in Q1 2019. 38 funds tracked by Wall St. Rank hold SPRO as of Q1 2025.

  • Virtu Financial reported no remaining Spero Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Virtu Financial sold 46,046 Spero Therapeutics shares in Q1 2025, an estimated $47K.
  • Virtu Financial first reported a position in Spero Therapeutics in Q1 2019 and held it in 5 quarters.
  • Virtu Financial's Spero Therapeutics position peaked at $134K in Q1 2019.
  • 38 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2025.

Based on Virtu Financial's 13F filing for Q1 2025, filed 12 May 2025.